Skip to main content

Table 1 Baseline demographics for clinical evaluation committee community-acquired pneumonia patients

From: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

  Tifacogin
n = 251
Placebo
n = 245
Selected
P value
Age in years, mean ± standard deviation 60.5 ± 15.8 60.2 ± 15.1  
Gender, number (percentage)    
   Female 91 (36) 100 (41)  
   Male 160 (64) 145 (59)  
Ethnicity, number (percentage)    
   Caucasian 207 (82) 199 (81)  
   Black 26 (10) 20 (8)  
   Hispanic 9 (4) 12 (5)  
   Asian 5 (2) 7 (3)  
   Other 4 (2) 7 (3)  
Baseline APACHE II score    
   Mean ± standard deviation 25.6 ± 7.0 25.2 ± 6.7  
Baseline interleukin-6 434.6 478.9  
   Geometric mean (95% CI) (329.2, 573.6) (355.1, 645.9)  
Baseline procalcitonin    
   Geometric mean (95% CI) 8.89 (7.15, 11.05) 8.09 (6.35, 10.31)  
   <2 ng/mL, number (percentage) 50 (20) 60 (25)  
Shock, number (percentage) 163 (65) 176 (72) 0.10
Ventilatory support, number (percentage) 193 (77) 200 (82) 0.19
Number of organ dysfunctions, number (percentage)    
   Two or less 87 (35) 72 (29) 0.21
   Three or more 164 (65) 173 (71)  
Heparin use, number (percentage) 172 (69) 167 (68)  
Organism identified, number (percentage) 170 (68) 154 (63)  
  1. APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval.